全文获取类型
收费全文 | 10235篇 |
免费 | 649篇 |
国内免费 | 63篇 |
专业分类
耳鼻咽喉 | 161篇 |
儿科学 | 272篇 |
妇产科学 | 206篇 |
基础医学 | 1407篇 |
口腔科学 | 474篇 |
临床医学 | 816篇 |
内科学 | 2370篇 |
皮肤病学 | 218篇 |
神经病学 | 741篇 |
特种医学 | 234篇 |
外科学 | 1544篇 |
综合类 | 71篇 |
现状与发展 | 1篇 |
一般理论 | 7篇 |
预防医学 | 959篇 |
眼科学 | 172篇 |
药学 | 711篇 |
中国医学 | 39篇 |
肿瘤学 | 544篇 |
出版年
2023年 | 59篇 |
2022年 | 147篇 |
2021年 | 276篇 |
2020年 | 191篇 |
2019年 | 317篇 |
2018年 | 346篇 |
2017年 | 227篇 |
2016年 | 252篇 |
2015年 | 282篇 |
2014年 | 350篇 |
2013年 | 412篇 |
2012年 | 617篇 |
2011年 | 665篇 |
2010年 | 378篇 |
2009年 | 329篇 |
2008年 | 510篇 |
2007年 | 589篇 |
2006年 | 561篇 |
2005年 | 474篇 |
2004年 | 444篇 |
2003年 | 375篇 |
2002年 | 375篇 |
2001年 | 258篇 |
2000年 | 332篇 |
1999年 | 249篇 |
1998年 | 91篇 |
1997年 | 60篇 |
1996年 | 44篇 |
1995年 | 55篇 |
1994年 | 64篇 |
1993年 | 50篇 |
1992年 | 121篇 |
1991年 | 132篇 |
1990年 | 116篇 |
1989年 | 118篇 |
1988年 | 95篇 |
1987年 | 84篇 |
1986年 | 83篇 |
1985年 | 97篇 |
1984年 | 56篇 |
1983年 | 43篇 |
1980年 | 34篇 |
1979年 | 57篇 |
1978年 | 61篇 |
1977年 | 32篇 |
1975年 | 52篇 |
1974年 | 57篇 |
1973年 | 43篇 |
1972年 | 35篇 |
1970年 | 32篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Lyra AC Soares MB dos Santos RR Lyra LG 《Gut》2007,56(11):1640; author reply 1640-1640; author reply 1641
992.
Ballesté B Bessa X Piñol V Castellví-Bel S Castells A Alenda C Paya A Jover R Xicola RM Pons E Llor X Cordero C Fernandez-Bañares F de Castro L Reñé JM Andreu M;Gastrointestinal Oncology Group of the Spanish Gastroenterological Association 《Diseases of the colon and rectum》2007,50(7):971-980
Purpose Patients with colorectal cancer have a high risk of developing metachronous neoplasms. Identification of predictive factors
associated with such conditions would allow individualized follow-up strategies in these patients. This study was designed
to identify individual and familial factors associated with the development of metachronous colorectal neoplasms in patients
with colorectal cancer.
Methods In the context of a prospective, multicenter, general population-based study—the EPICOLON project—all patients with colorectal
cancer attended in ten Spanish hospitals during a one-year period were included. Patients with familial adenomatous polyposis
or inflammatory bowel disease were excluded. All patients were monitored by colonoscopy within two years of the diagnoses.
Demographic, clinical, pathologic, molecular (microsatellite instability status and immunohistochemistry for MSH2 and MLH1),
and familial characteristics (fulfillment of Amsterdam I or II criteria, and revised Bethesda guidelines) were analyzed.
Results A total of 353 patients were included in the study. At two years of follow-up, colonoscopy revealed the presence of adenomas
in 89 (25 percent) patients and colorectal cancer in 14 (3.9 percent) patients, in 7 cases restricted to anastomosis. Univariate
analysis demonstrated that development of metachronous neoplasm (adenoma or colorectal cancer) was associated with personal
history of previous colorectal cancer (odds ratio, 5.58; 95 percent confidence interval, 1.01–31.01), and presence of previous
or synchronous adenomas (odds ratio, 1.77; 95 percent confidence interval, 1.21–3.17). Although nonstatistical significance
was achieved, metachronisms were associated with gender (P < 0.09) and differentiation degree (P < 0.08). Multivariate analysis identified previous or synchronous adenomas (odds ratio, 1.98; 95 percent confidence interval,
1.16–3.38) as independent predictive factor. Neither presence of tumor DNA microsatellite instability nor family history correlated
with the presence of metachronous neoplasms.
Conclusions Patients with previous or synchronous colorectal adenoma have an increased risk of developing metachronous colorectal neoplasms.
Accordingly, this subgroup of patients may benefit from specific surveillance strategies.
Supported by grants from the Red Nacional de Investigación en Hepatología y Gastroenterología (Instituto de Salud Carlos III,
C03/02) and from Fondo de Investigaciones Sanitarias (FIS PI061384). Xavier Llor is a recipient of a Ramon y Cajal grant form
Ministerio de Ciencia y Tecnología of the Spanish government
Presented at the meeting of the United European Gastroenterology, Copenhagen, Denmark, October 15 to 19, 2005. 相似文献
993.
We investigated the relationship between complement component 3 (C3), fasting and postprandial lipemia and the metabolic syndrome (MetabS). Herefore fasting and postprandial samples after an acute oral fat load were obtained in 40 MetabS+ (50+/-8 years) and 70 MetabS- (48+/-7 years) subjects. Fasting C3 was higher in MetabS+ (1.21+/-0.33g/L versus 0.91+/-0.14g/L, P<0.001). Postprandially, MetabS+ had a higher total and incremental triglyceride response (TG-AUC: +77%; P<0.001 and TG-dAUC: +48%; P<0.05, respectively) and a higher total free fatty acid (FFA-AUC: +13%, P<0.05) and C3 response (C3-AUC: +26%, P<0.001) when compared to MetabS-. In both groups, fasting C3 was strongly associated with fasting TG, TG-AUC, TG-dAUC and insulin sensitivity (HOMA) (R=0.68, 0.67, 0.41 and 0.67, respectively, for the whole group; P<0.001 for each). Fasting C3 showed a dose-dependent relation with the number of MetabS components and, following exclusion of these components, it was after TG-AUC, the second best determinant of the MetabS (adjusted R(2)=0.47, P<0.001). In conclusion, C3 and postprandial lipema are closely associated with the metabolic syndrome and with several metabolic variables linked to insulin resistance. C3 may be a useful marker to identify subjects with the metabolic syndrome. 相似文献
994.
995.
996.
997.
998.
Sousa NC Anicchino-Bizzacchi JM Locatelli MF Castro V Barjas-Castro ML 《Haematologica》2007,92(2):236-239
The aim of this study was to correlate ABO groups with plasma levels of factor VIII (FVIII), von Willebrand factor (VWF:Ag), and ristocetin cofactor (VWF:RCo). Serological and molecular tests defined blood groups from 114 donors (10 AA, 10 BB, 10 AB, 10 AO1, 10 BO1,16 O1O1, 20 A2O1, 20 A2B, 4 A3O1, 3 AxO1, and 1 BelO1). The levels of VWF:Ag, FVIII and VWF:RCo observed in rare subgroups (A3O1, AxO1, BelO1) were similar to the values found in the O1O1 group. However, levels of these factors were significantly higher in A2O1 donors than in O1O1 donors (VWF:Ag p=0.01; FVIII p=0.04; VWF:RCo p<0.001). Strong correlations were demonstrated between plasma levels of VWF:Ag and FVIII (R=0.77; p=0.001) and between VWF:Ag and VWF:RCo (R=0.75; p=0.001). 相似文献
999.
1000.
Glucocorticoids (GC) are a mainstay of the therapy in rheumatoid arthritis (RA). Currently, and despite their extensive use, the discussion about the benefits and adverse effects of low dose GC in the management of RA persists. In recent years, a number of clinical trials have attempted to establish the benefits of long-term GC use as a disease-modifying antirheumatic drug in RA, and to define their side effects. Results of these clinical trials provide solid evidence that low-dose GC can inhibit radiographic damage in early RA, and that side effects of GC, when used in that clinical framework, are limited to hyperglycaemia, cataracts, and transient weight gain. 相似文献